Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02827708 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
NCT02827708 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 324 participants.
The verdict
NCT02827708, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
Interventions
- DRUG placebo
- DRUG semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02827708
The ClinicalTrials.gov registry entry for NCT02827708 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02827708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02827708 about?
NCT02827708 is a clinical study titled "Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment". This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
What is the current status of trial NCT02827708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2016-09-20. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT02827708?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG).
Who is sponsoring clinical trial NCT02827708?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.